De-Wei An, Yu-Ling Yu, Dries S. Martens, Agnieszka Latosinska, Zhen-Yu Zhang, Harald Mischak, Tim S. Nawrot, Jan A. Staessen
{"title":"适用于管理 OMICS 数据的统计方法:以尿液蛋白质组学为例","authors":"De-Wei An, Yu-Ling Yu, Dries S. Martens, Agnieszka Latosinska, Zhen-Yu Zhang, Harald Mischak, Tim S. Nawrot, Jan A. Staessen","doi":"10.1002/mas.21849","DOIUrl":null,"url":null,"abstract":"<p>With urinary proteomics profiling (UPP) as exemplary omics technology, this review describes a workflow for the analysis of omics data in large study populations. The proposed workflow includes: (i) planning omics studies and sample size considerations; (ii) preparing the data for analysis; (iii) preprocessing the UPP data; (iv) the basic statistical steps required for data curation; (v) the selection of covariables; (vi) relating continuously distributed or categorical outcomes to a series of single markers (e.g., sequenced urinary peptide fragments identifying the parental proteins); (vii) showing the added diagnostic or prognostic value of the UPP markers over and beyond classical risk factors, and (viii) pathway analysis to identify targets for personalized intervention in disease prevention or treatment. Additionally, two short sections respectively address multiomics studies and machine learning. In conclusion, the analysis of adverse health outcomes in relation to omics biomarkers rests on the same statistical principle as any other data collected in large population or patient cohorts. The large number of biomarkers, which have to be considered simultaneously requires planning ahead how the study database will be structured and curated, imported in statistical software packages, analysis results will be triaged for clinical relevance, and presented.</p>","PeriodicalId":206,"journal":{"name":"Mass Spectrometry Reviews","volume":"43 6","pages":"1237-1254"},"PeriodicalIF":6.9000,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mas.21849","citationCount":"0","resultStr":"{\"title\":\"Statistical approaches applicable in managing OMICS data: Urinary proteomics as exemplary case\",\"authors\":\"De-Wei An, Yu-Ling Yu, Dries S. Martens, Agnieszka Latosinska, Zhen-Yu Zhang, Harald Mischak, Tim S. Nawrot, Jan A. Staessen\",\"doi\":\"10.1002/mas.21849\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>With urinary proteomics profiling (UPP) as exemplary omics technology, this review describes a workflow for the analysis of omics data in large study populations. The proposed workflow includes: (i) planning omics studies and sample size considerations; (ii) preparing the data for analysis; (iii) preprocessing the UPP data; (iv) the basic statistical steps required for data curation; (v) the selection of covariables; (vi) relating continuously distributed or categorical outcomes to a series of single markers (e.g., sequenced urinary peptide fragments identifying the parental proteins); (vii) showing the added diagnostic or prognostic value of the UPP markers over and beyond classical risk factors, and (viii) pathway analysis to identify targets for personalized intervention in disease prevention or treatment. Additionally, two short sections respectively address multiomics studies and machine learning. In conclusion, the analysis of adverse health outcomes in relation to omics biomarkers rests on the same statistical principle as any other data collected in large population or patient cohorts. The large number of biomarkers, which have to be considered simultaneously requires planning ahead how the study database will be structured and curated, imported in statistical software packages, analysis results will be triaged for clinical relevance, and presented.</p>\",\"PeriodicalId\":206,\"journal\":{\"name\":\"Mass Spectrometry Reviews\",\"volume\":\"43 6\",\"pages\":\"1237-1254\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2023-05-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mas.21849\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mass Spectrometry Reviews\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/mas.21849\",\"RegionNum\":2,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SPECTROSCOPY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mass Spectrometry Reviews","FirstCategoryId":"92","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mas.21849","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SPECTROSCOPY","Score":null,"Total":0}
引用次数: 0
摘要
本综述以尿液蛋白质组学分析(UPP)作为全息技术的典范,介绍了在大型研究人群中分析全息数据的工作流程。建议的工作流程包括(i) omics 研究规划和样本量考虑;(ii) 准备分析数据;(iii) UPP 数据预处理;(iv) 数据整理所需的基本统计步骤;(v) 协变量的选择;(vi) 将连续分布或分类结果与一系列单一标记物(如:测序的尿肽片段)相关联、(vii) 显示 UPP 标记在传统风险因素之外的附加诊断或预后价值,以及 (viii) 通过路径分析确定疾病预防或治疗的个性化干预目标。此外,还有两个小节分别讨论了多组学研究和机器学习。总之,与 omics 生物标志物相关的不良健康结果分析与在大型人群或患者队列中收集的任何其他数据一样,都基于相同的统计原理。由于需要同时考虑大量的生物标记物,因此需要提前规划如何构建和管理研究数据库、如何将其导入统计软件包、如何对分析结果进行临床相关性筛选以及如何进行展示。
Statistical approaches applicable in managing OMICS data: Urinary proteomics as exemplary case
With urinary proteomics profiling (UPP) as exemplary omics technology, this review describes a workflow for the analysis of omics data in large study populations. The proposed workflow includes: (i) planning omics studies and sample size considerations; (ii) preparing the data for analysis; (iii) preprocessing the UPP data; (iv) the basic statistical steps required for data curation; (v) the selection of covariables; (vi) relating continuously distributed or categorical outcomes to a series of single markers (e.g., sequenced urinary peptide fragments identifying the parental proteins); (vii) showing the added diagnostic or prognostic value of the UPP markers over and beyond classical risk factors, and (viii) pathway analysis to identify targets for personalized intervention in disease prevention or treatment. Additionally, two short sections respectively address multiomics studies and machine learning. In conclusion, the analysis of adverse health outcomes in relation to omics biomarkers rests on the same statistical principle as any other data collected in large population or patient cohorts. The large number of biomarkers, which have to be considered simultaneously requires planning ahead how the study database will be structured and curated, imported in statistical software packages, analysis results will be triaged for clinical relevance, and presented.
期刊介绍:
The aim of the journal Mass Spectrometry Reviews is to publish well-written reviews in selected topics in the various sub-fields of mass spectrometry as a means to summarize the research that has been performed in that area, to focus attention of other researchers, to critically review the published material, and to stimulate further research in that area.
The scope of the published reviews include, but are not limited to topics, such as theoretical treatments, instrumental design, ionization methods, analyzers, detectors, application to the qualitative and quantitative analysis of various compounds or elements, basic ion chemistry and structure studies, ion energetic studies, and studies on biomolecules, polymers, etc.